Research Progress in Metabolomics in Different Molecular Subtypes of Breast Cancer

Treatment and prognosis of breast cancer are significantly affected by molecular subtyping, which can improve the precision of breast cancer diagnosis and treatment by clarifying molecular subtypes. Metabolomics is an omics technology developed following genomics, transcriptomics and proteomics, and it is widely used for the screening of tumor biomarkers and disease diagnosis. In recent years, studies had found heterogeneity in metabolic reprogramming among breast cancer subtypes. Biomarkers were uncovered by metabolomics that provided some highly specific, sensitive and selective visual indicators for the early diagnosis, prognostic assessment, drug target and mechanism studies, and toxicology studies of molecular subtypes of breast cancer. This paper reviews metabolic markers that can be used as various molecular subtypes of breast cancer and expects to provide a new idea for the diagnosis and precise treatment of different subtypes of breast cancer.